MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'aggrenox'. Sat, 03 Sep 2011 02:59:49 +0100 http://www.medworm.com/index.php?rid=3683870&cid=t_153198_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FQ3WgLWefK3Q%2F Four years ago, Boehringer Ingelheim set out to prove that its Aggrenox heart drug could beat a basic dose of aspirin in preventing strokes. The results came back in March, but the drugmaker hasn’t worked very hard to publicize them. Why? The trial was a bust - Aggrenox failed to meet the primary endpoint of reducing the risk of secondary ischemic stroke in 1,294 patients in Japan. The incidence among patients given Aggrenox was 6.9 percent compared with 5 percent for those on aspirin (look here). This is a problem for Boehringer, which markets Aggrenox to “reduce the risk of a subsequent stroke in patients who have had a transient ischemic attack, or TIA, or stroke due to a blood clot.” After all, Aggrenox is rather pricey, costing about $3 per pill, and it must be taken... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3683870 Mon, 21 Jun 2010 12:52:49 +0100 3683870 http://www.medworm.com/index.php?rid=1739493&cid=t_153198_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F377020749%2F Nice to see you again. A holiday weekend is closing in rapidly, but interesting items continue to appear. So who knows what today brings? Our betting is that many people will be scrambling to clear their desks. Meanwhile, we will keep watch. So, here you go… Boehringer Drugs Disappoint In Stroke Study (Bloomberg News) Hundreds Complain About Reformulated Glaxo Drug (National Business Review) India’s Sun Pharma Closer To Buying Taro (The Business Standard) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1739493 Thu, 28 Aug 2008 10:41:14 +0100 1739493 http://www.medworm.com/index.php?rid=1623002&cid=t_153198_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F335054868%2F The move comes two months after the drugmaker released disappointing results of a large study of its Aggrenox blood thinner, which failed to meet its primary endpoint, and Barr Pharmaceuticals won a patent challenge on Mirapex, a med for restless leg syndrome, suggesting a generic rival is looming. The neurology sales team, which peddles Aggrenox to neurologists for treating transient ischemic attacks and strokes, met last week in Chicago, where BI managers told them they are going to restructure. The bad news was delivered in lieu of a celebration of the Profess trial, which BI originally hoped would help Aggrenox grab market share from Plavix, the most widely used blood thinner. The reps were told that about 200 of them - or about half of the neuro sales team - may be shifted to primary... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1623002 Mon, 14 Jul 2008 12:26:56 +0100 1623002 http://www.medworm.com/index.php?rid=1446420&cid=t_153198_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F291692326%2F File this under How To Sink Your Own Boat. The drugmaker earlier this week released the long-awaited results of a large study involving two of its meds - the Micardis hypertension tablets and the Aggrenox blood thinner - and the outcome may, instead, thin employee ranks and give investors high blood pressure. The widely touted Profess trial, which was presented at the European Stroke Conference in Nice, France, looked at 20,333 patients in 35 countries. However, according to BI’s rationale, the entire effort was a bust. First, Aggronex failed to meet its primary endpoint - Plavix, far and away the most widely used blood thinner, was superior in secondary stroke prevention. Aggronex, by the way, generated about $400 million in worldwide sales last year. Another arm looked at whether ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1446420 Fri, 16 May 2008 15:08:46 +0100 1446420 http://www.medworm.com/index.php?rid=1446055&cid=t_153198_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F05%2Fboehringer-ingelheim-clinical-trials.html Said through gritted teeth:"We are proud to have sponsored the PRoFESS study," said Dr. Thor Voigt, Senior Vice President, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc."We set out to advance the understanding of strategies for recurrent stroke prevention and will continue to evaluate the PRoFESS data to help physicians make more informed treatment decisions."The Trial:PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) was designed to examine the effects of different prevention regimens on recurrent stroke, including the antiplatelet agent AGGRENOX versus clopidogrel and the efficacy of MICARDIS, an antihypertensive, compared to placebo in preventing recurrent stroke in the presence of background standard antihypertensive therapy. The tri... PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1446055 Thu, 15 May 2008 19:34:00 +0100 1446055 http://www.medworm.com/index.php?rid=968377&cid=t_153198_122_f&fid=35055&url=http%3A%2F%2Fsarasotaneurology.com%2F2007%2F10%2F22%2Fstroke-prevention-a-better-way-of-stroke-treatment%2F The objective is to have a total cholesterol less than 180, good cholesterol (HDL) of greater than 50 and bad cholesterol (LDL) less than 100. A recent study published in the journal Stroke reported that discontinuing statin therapy in the year after a stroke is associated with a significant increase in the risk for death, even in the absence of heart disease. Medications are not the only treatment for stroke prevention. Smoking is associated with a 2-3 times greater risk of stroke and bleeding in the brain. Smoking also contributes to the accelerated development of heart disease, emphysema and peripheral artery disease. Chantix is a new medication that received FDA approval to help stop smoking. Exercise is important in maintaining overall body conditioning and weight control. This in tur... Sarasota Neurology blogs http://www.medworm.com/rss/comments.php?id=968377 Mon, 22 Oct 2007 11:15:34 +0100 968377